Pre-Clinical ResearchA Dipeptidyl Peptidase-4 Inhibitor, Des-Fluoro-Sitagliptin, Improves Endothelial Function and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E–Deficient Mice
Under an Elsevier user license
open archive
Key Words
atherosclerosis
dipeptidyl peptidase-4 inhibitors
endothelium
glucagon-like peptide 1 receptor
inflammation
receptors
Abbreviations and Acronyms
apoE
apolipoprotein E
CAD
coronary artery disease
cAMP
cyclic adenosine monophosphate
DFS
des-fluoro-sitagliptin
DM
diabetes mellitus
DPP
dipeptidyl peptidase
eNOS
endothelial nitric oxide synthase
ERK
extracellular signal-regulated kinase
GLP
glucagon-like peptide
HCAEC
human coronary artery endothelial cell
HFD
high-fat diet
IL
interleukin
JNK
c-jun N-terminal kinase
LPS
lipopolysaccharide
mRNA
messenger ribonucleic acid
NF-κB
nuclear factor–kappa B
PKA
protein kinase A
Cited by (0)
This study was supported in part by a grant-in-aid for scientific research (grant C22590786 to Dr. Sugiyama) from the Ministry of Education, Science, and Culture of Japan and grant support from Merck & Company, Inc. All authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.